Clinical trial
INNO-206 in Patients With Small Cell Lung Cancer (SCLC)
NCT00472771 · CytRx, Industry · Withdrawn
Key facts
| NCT number | NCT00472771 |
|---|---|
| Title | INNO-206 in Patients With Small Cell Lung Cancer (SCLC) |
| Official title | A Phase II, Open-label Study of INNO-206 in Patients With Recurrent Extensive Small Cell Lung Cancer After First-line Platinum-based Therapy |
| Lead sponsor | CytRx, Industry |
| Status | Withdrawn |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Small Cell Lung Cancer |
| Intervention type | Drug |
| Interventions | INNO-206 |
| Enrollment | 0 |
| Start date | May 1, 2008 |
| Completion | Nov 1, 2008 |
| First posted | May 14, 2007 |
| Last update posted | Feb 9, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: